It has been established that in comorbid (cardiopulmonary) pathology in horses with asthma patients develop a syndrome of airway obstruction, morphofunctional changes in the erythrocyte system, impaired blood gas transmission function, increased permeability of cell membranes, which leads to complications in the form of myocardiodystrophy and cardiac failure. The use of a complex treatment regimen for horses with asthma and complicated myocardiodystrophy contributed to reducing attacks of respiratory dysfunction and symptoms of heart failure, reducing the incidence of arrhythmias and valvular regurgitation, reducing the number of neutrophils in the BAL washings, and reducing indicators characteristic of tissue hypoxia, (decrease in the number of erythrocytes, hemoglobin, hematocrit, mean corpuscular volume and mean corpuscular hemoglobin), elimination of the inflammatory process in the respiratory tract (decrease in the number of leukocytes, stab and segmented neutrophils), a decrease in the indices characterizing the integrity of the cardiomyocyte membranes (decrease in the activity of CК, CК-MB, LDH, LDH-1), restoration of diffuse capacity of the lungs (decrease in pH and increase in pO2 and pCO2 of blood). The mechanism of the positive effect of drugs that were used to treatment of horses with asthma syndrome with complicated myocardiodystrophy, which is achieved due to the cardio metabolic (cytoprotective) effect and antihypoxic ability to improve the diffusion of gases through the alveolar-capillary membrane, is established. On the one hand, it improves metabolic processes in the myocardium and, accordingly, reduces the manifestations of heart failure, and on the other hand, reduces hypoxia and respiratory failure (respiratory dysfunction), as one of the central pathogenetic mechanisms of cardiorespiratory comorbidity.